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Purpose. It has been reported that Th2 cytokines downregulate antitumor immunity, while activation of type T cells promotes
antitumor immunity. The aim of this paper was to evaluate host immunity in liver cirrhosis (LC) patients with advanced
hepatocellular carcinoma (aHCC) receiving sorafenib therapy. Methods. Forty-ﬁve adult Japanese LC patients received sorafenib
for aHCC between 2009 and 2011 at our hospital. Sorafenib was administered at a dose of 200–800mg/day for 4 weeks. Blood
samples were collected before and after treatment. Results. Eleven patients were treated with sorafenib at 200mg/day (200 group),
27 patients received sorafenib at 400mg/day (400 group), and 7 patients were given sorafenib at 800mg/day (800 group). There
was no signiﬁcant change in the percentage of Th1 cells after treatment in any group. However, the percentages of Th2 cells and
regulatory T cells were signiﬁcantly decreased after treatment in the 400 group and 800 group compared with before treatment,
although there was no signiﬁcant change after treatment in the 200 group. Conclusions. These results indicate that treatment with
sorafenib might induce Th1 dominance and prevent the escape of tumor cells from the host immune system in LC patients with
aHCC.
1.Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common
malignancy in men and the eighth most common in women,
withover500,000newcasesbeingdiagnosedworldwideeach
year [1–3]. Several therapeutic modalities, including surgery,
percutaneous ethanol injection (PEI), transcatheter arterial
chemoembolization (TACE), and radiofrequency ablation
(RFA), are used to treat small tumors. Recently, the oral mu-
ltikinase inhibitor sorafenib, which shows strong in vitro
activity by targeting the Raf/mitogen-activated protein
kinase/extracellular signal-related kinase signaling pathway,
has been used to treat advanced hepatocellular carcinoma
(aHCC). In the Sorafenib HCC Assessment Randomised
Protocol (SHARP) study, 602 patients (mainly Europeans)
were randomized to receive sorafenib or placebo. They had
an Eastern Cooperative Oncology Group performance status
of 0–2 and were all in Child-Pugh class A. The sorafenib
group achieved a median overall survival time of 10.7
months versus 7.9 months for the placebo group [4]. Sorafe-
nib has also demonstrated signiﬁcant clinical activity against
HCC in phase II and phase III studies [5, 6], in which treat-
ment with this agent achieved a longer median survival time
and longer time to radiologic progression compared with
placebo.
When treating aHCC in patients with cirrhosis of the
liver, we must consider the inﬂuence of tumor-related fac-
tors, the properties of the anticancer drugs or molecular-tar-
geting agents, and host immunity. Tumors develop various
mechanisms to escape from the host immune system and to
inhibit antitumor responses. Dendritic cells (DCs) are the
most potent antigen-presenting cells with respect to their
ability to eﬃciently prime both CD4-positive and CD8-posi-
tive cytotoxic T cells. It has been reported that impaired DC
function might be an important factor in allowing tumors
to escape from surveillance [7], and that the number of2 Clinical and Developmental Immunology
peripheral blood DCs is signiﬁcantly decreased in cancer
patients [8, 9]. Production of immunosuppressive factors, an
increaseofregulatory(Treg)cells,anddownregulationofthe
expression of tumor antigens and major histocompatibility
complex (MHC) molecules are some of the mechanisms by
which tumor cells can escape from immune recognition [10,
11]. All of these mechanisms may operate in patients with
HCC. Based on their cytokine production proﬁles, helper T
cells can be divided into two distinct populations, which are
knownastype1helperTcells(Th1cells)andtype2helperT
cells (Th2 cells). Th1 cells produce interferon-gamma (IFN-
gamma) and interleukin 2 (IL-2) and play a pivotal role in
cell-mediated immunity, while Th2 cells produce interleukin
4 (IL-4), interleukin 10 (IL-10), and other cytokines that are
essential for the regulation of humoral immunity [12, 13].
The Th1 subset is responsible for activation of cell-mediated
immunity and cytotoxic CD8+ T lymphocytes (CTLs),
while the Th2 subset primarily assists in B cell activation
[14]. The direction in which naive CD4+ cells diﬀerentiate
depends on their ﬁrst encounter with the triggering agents.
The factors regulating diﬀerentiation are still not fully
understood, although the cytokine environment during the
diﬀerentiation of antigen-primed CD4+ T helper cells is
thought to determine the subset that emerges [15]. IFN-
gamma preferentially inhibits the proliferation of Th2 cells,
while IL-4 and IL-10 are secreted by Th2 cells and suppress
the secretion of IL-12, which is the critical cytokine for
Th1 diﬀerentiation [16, 17]. Thus, Th1 and Th2 cells cross-
regulate their own development. It has been reported that
Th2 cytokines inhibit antitumor immunity [18], while the
activation of Th1 responses promotes antitumor immunity
[19–22]. We have previously shown that Th1 dominance is
lost due to an increase of Th2 cells in HCC patients, and
that carcinogenesis might be more likely to occur in patients
with chronic HCV infection and an increase of Th2 cells
[23]. The response of T cells to self-and nonself-antigens
is controlled by a network of Treg cells. CD4+ cells that
constitutively express CD25, the interleukin-2-receptor α-
chain, are generally considered to be natural Treg cells and
account for 5–10% of all peripheral CD4+ T cells in healthy
animals and humans [24–26].
We previously examined the changes of host immunity
and eﬃcacy of treatment in LC patients with aHCC receiving
hepatic intra-arterial chemotherapy (HAIC). We found that
the percentage of Th2 cells increased in liver cirrhosis (LC)
patients with aHCC as the response to HAIC decreased. This
suggested that HAIC might be not useful for patients with
aHCC because it induces Th2 dominant host immunity [27,
28]. However, it is not clear how sorafenib inﬂuences host
immunity in LC patients with aHCC. Accordingly, the aim
ofthepresentstudywastoretrospectivelyevaluatechangesof
hostimmunity inLCpatients withaHCCreceivingsorafenib
therapy.
2. Methods
2.1. Patients. Forty-ﬁve adult Japanese LC patients were
treated for an aHCC with sorafenib between 2009 and 2011
at our hospital. Sorafenib was administered at a dose of 200–
800mg/day for 4 weeks depending on the patient’s body
habitus and age. Blood samples were collected in the early
morning before and after treatment.
2.2. Analysis of CD4-Positive T Cell Subsets. Peripheral blood
CD4-positive T cell subsets were analyzed after nonspeciﬁc
stimulation with phorbol 12-myristate 13-acetate (PMA),
ionomycin, or brefeldin A (Sigma Chemical Co., St. Louis,
MO, USA), according to the modiﬁed method of Jung et
al. [29]. Flow cytometry was used to detect cytoplasmic
expression of IFN-gamma and IL-4 by peripheral blood
CD4-positive T cells after culture and staining, as reported
previously. Results were expressed as the percentage of
cytokine-producing cells in the CD4-positive T cell popu-
lation, which was divided into IFN-gamma-positive/IL-4-
negative (Th1) cells and IFN-gamma-negative/IL-4-positive
(Th2) cells (Figure 1). Regulatory T cells (Treg cells) were
identiﬁed as CD25high/CD127low cells (Figure 2).
2.3. Evaluation of Tumor Response. Tumor responses were
assessed according to the modiﬁed Response Evaluation
Criteria in Solid Tumors (RECIST) [30, 31].
2.4. Statistical Analysis. Statistical analysis was performed by
using the Statistical Package for the Social Sciences (SPSS
version 11.0; SPSS, Chicago, IL, USA). Results are expressed
as the mean ± standard deviation (SD). Wilcoxon’s signed
rank sum test was used to compare patient characteristics
within each group. A probability of less than 0.05 was
considered to indicate statistical signiﬁcance in all analyses.
3. Results
The 45 patients were divided into three groups. Eleven
patients were administered sorafenib at a dose of 200mg/day
for 4 weeks (200 group), 27 patients were administered
400mg/day for 4 weeks (400 group), and 7 patients were
administered 800mg/day for 4 weeks (800 group). There
w e r e7m e na n d4w o m e na g e d6 0t o8 2y e a r s( m e a n± SD:
72.1 ± 7 years) in the 200 group, 24 men and 3 women
aged 56 to 79 years (mean ± SD: 69.4 ± 6 years) in the 400
g r o u p ,a n d7m e na g e d6 1t o8 0y e a r s( m e a n± SD: 66.1 ±
7 years) in the 800 group. In the 200 group, eight patients
had HCV-related LC (C-LC), one patient had HBV-related
LC (B-LC), and two patients had non-B non-C LC (non-
B non-LC), which did not include LC due to autoimmune
diseases such as autoimmune hepatitis or primary biliary
cirrhosis. In the 400 group, there were 17 patients with C-
LC, 5 patients with B-LC, and 5 patients with non B non-C
LC. In the 800 group, 1 patient had C-LC, 2 patients had B-
LC, and 4 patients had non B non-C LC. The Child-Pugh
class was A for 8 patients in the 200 group, 26 patients in the
400 group, and 5 patients in the 800 group, while it was B
for 3, 1, and 2 patients, respectively. Nine patients had stage
IVA disease and two patients had stage IVB disease in the 200
group. There was 1 patient with stage III disease, 24 patients
with stage IVA disease, and 2 patients with stage IVB diseaseClinical and Developmental Immunology 3
104
104
103
103
102
102
101
101 100
100
4.7% 2.7%
I
L
-
4
61.3% 31.3%
Quad Events Gated (%)
UL
UR
LL
LR
293
166
3838
1961
4.7
2.7
61.3
31.3
IFN-γ/IL−4 in CD4
IFN-γ
Figure 1: Flow cytometric detection of interferon (IFN-γ) and interleukin (IL-4) in CD4-positive T cells. Upper left: IFN-γ-negative and
IL-4-positive cells (Th2); lower right: IFN-γ-positive and IL-4-negative cells (Th1).
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Table 1: Clinical characteristics of 45 liver cirrhosis patients with
HCC.
Dose of sorafenib 200mg 400mg 800mg
No. of patients 11 27 7
Mean age 72.1 ± 7 69.4 ± 6 66.1 ± 7
Gender
(M/F) 7/4 24/3 7/0
Type of cirrhosis
(HBV/HCV/non B non C) 1/8/2 5/17/5 2/1/4
Child-Pugh classiﬁcation
(A/B/C) 8/3/0 26/1/0 5/2/0
Stage
(III/IVAIIVB) 0/9/2 1/24/2 0/7/0
JIS score
(2/3/4/5) 0/8/3/0 0/26/1/0 0/5/2/0
Table 2:Objectiveresponsesoflivercirrhosispatientswithadvanc-
ed HCC treated after 4–8 weeks of sorafenib treatment.
Dose of sorafenib PR SO PO Response rate (%)
200m g (n = 11)
(1 dropout) 028 0 . 0
400mg (n = 27)
(3 dropout) 4 11 9 16.7
800mg (n = 7)
(0 dropout) 1 3 3 14.3
in the 400 group, while all 7 patients had stage IVA disease in
the 800 group. Eight patients had a Japan Integrated Staging
(JIS) score [32] of 3, and three patients had a score of 4 in
the 200 group, while the respective numbers were 26 and 1 in
the 400 group, as well as 5 and 2 in the 800 group (Table 1).
In the 200 group, one patient had involvement of the major
branches of the portal vein, and there were no patients with
portal trunk thrombus, while the respective numbers were 3
and 4 in the 400 group, as well as 1 and 1 in the 800 group. In
the 800 group, one patient had invasion of the main hepatic
venous trunk.
3.1.Response. Table 2 summarizestheresponsetotreatment.
In the 200 group, 8 of the 11 patients (72.7%) showed pro-
gressive disease (PD) and 2 patients (18.2%) had stable dis-
ease (SD), but no patient achieved a partial response (PR).
In the 400 group, 4 of the 27 patients (14.8%) achieved PR,
while 9 patients (33.3%) showed PD and 11 patients (40.7%)
had SD. In the 800 group, 1 of the 7 patients (14.3%) achiev-
ed PR, while 3 patients (42.9%) patients showed PD and 3
patients (42.9%) had SD.
3.2.PeripheralBloodTh1andTh2Cells. Therewerenosigni-
ﬁcant diﬀerences of Th1 cells between before treatment (200
group: 26.3 ± 8%; 400 group: 27.6 ± 11%; 800 group: 27.7
± 17%) and after treatment (200 group: 23.8 ± 10%; 400
group: 24.9 ± 11%; 800 group: 28.7 ± 18%) in each of the 3
groups (Figure 3). In contrast, signiﬁcant diﬀerences of Th2
cells were noted in the 400 and 800 groups between before
treatment (400 group: 3.9 ± 2%; 800 group: 3.7 ± 1%) and
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Figure 3: Comparison of the IFN-γ-positive and IL-4-negative
(Th1) subset of CD4-positive T cells before and after treatment in
the 200 group, 400 group, and 800 group. There were no signiﬁcant
diﬀerences between before and after treatment in any group.
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Figure 4: Comparison of the IFN-γ negative and IL-4 positive
(Th2) subset of CD4-positive T cells before and after treatment in
the 200 group, 400 group, and 800 group. There were signiﬁcant
diﬀerences of Th2 cells between before and after treatment in the
400 group and 800 groups (P<0.05 by Wilcoxon’s signed rank sum
test), but there was no signiﬁcant diﬀerence of 14 Th2 cells in the
200 group.
after treatment (400 group: 3.5 ± 2%; 800 group: 3.3 ± 1%)
(P = 0.014 and P = 0.028, respectively, by Wilcoxon’s signed
rank sum test), although there was also no signiﬁcant diﬀer-
ence of Th2 cells between before and after treatment (3.1 ±
1% versus 3.3 ± 3%) in the 200 group (Figure 4).
3.3.PeripheralBloodTregCells. Thereweresigniﬁcantdiﬀer-
ences of Treg cells in the 400 and 800 groups between before
treatment (400 group: 9.5 ± 3%; 800 group: 8.5 ± 3%) and
after treatment (400 group: 9.2 ± 3%; 800 group: 7.3 ± 3%)
(P = 0.026 and P = 0.028, respectively, by Wilcoxon’s signed
rank sum test), but there was also no signiﬁcant diﬀerence
of Th2 cells between before and after treatment (10.0 ± 2%
versus 10.1 ± 3%) in the 200 group (Figure 5).Clinical and Developmental Immunology 5
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Figure 5: Comparison of CD25 FITC and CD127 PE among CD4-
positive T cells (Treg cells) before and after treatment. There were
signiﬁcant diﬀerences of Treg cells between before treatment and
aftertreatmentinthe400groupand800groups(P<0.05byWilco-
xon’s signed rank sum test), but there was no signiﬁcant diﬀerence
of Th2 cells in the 200 group.
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Figure 6: Comparison of the IFN-γ-positive and IL-4-negative
(Th1) subset of CD4-positive T cells before and after treatment in
the PR + SD group and PD group. There were no signiﬁcant diﬀer-
ences of Th1 cells between before treatment and after treatment in
either group.
3.4. Host Immunity and Objective Response. There were no
signiﬁcant diﬀerences of Th1 cells between before treatment
(PR + SD group: 26.2 ± 11%; PD group: 26.8 + 10%) and
after treatment (PR + SD group: 26.2 ± 12%; PD group:
26.3 ± 12%) in either group (Figure 6). However, there were
signiﬁcant diﬀerences of Th2 cells in the PR + SD and PD
groups between before treatment (PR + SD group: 4.2 ± 2%;
PD group: 3.6 ± 1%) and after treatment (PR + SD group:
3.7 ± 2%, P = 0.017; PD group: 3.1 ± 1%, P = 0.020)
(Figure 7). There were no signiﬁcant diﬀerences of Treg cells
between before treatment (PR + SD group: 8.9 ± 2%; PD
group: 9.6 ± 3%) and after treatment (PR ± SD group: 8.6 ±
2 % ;P Dgr o u p :9 . 3± 3%) in either group, although Treg cells
decreased after treatment in both groups 14 (Figure 8).
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Figure 7: Comparison of the IFN-γ-negative and IL-4-positive
(Th2) subset of CD4-positive T cells before and after treatment in
thePR+SDgroupandPDgroup.Thereweresigniﬁcantdiﬀerences
of Th2 cells in the PR + SD and PD groups between before treat-
ment and after treatment (PR + SD group: P = 0.017, PD group:
P = 0.020 by Wilcoxon’s signed rank sum test).
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Figure 8: Comparison of CD25 FITC and CD127 PE among
CD4-positive T cells (Treg cells) before and after chemotherapy.
There were no signiﬁcant diﬀerences of Treg cells between before
treatment and after treatment in either group, although Treg cells
decreased after treatment in both groups.
4. Discussion
The oral multikinase inhibitor sorafenib has revolutionized
the treatment of aHCC in patients with LC. It has been
reported that sorafenib therapy prolongs the median overall
survival of patients with aHCC [4], but there have been few
reports about the inﬂuence of sorafenib on host immunity in
a HCC patients. Kohga et al. demonstrated that a disintegrin
and metalloproteinase 9 (ADAM9) were overexpressed in
human HCC tissues, while ADAM9 knockdown increased
the expression of membrane-bound MHC class I-related
chain A (MICA), decreased the production of soluble MICA,
and increased the sensitivity of human HCC cells to natural
killer (NK) cells. Furthermore, they indicated that sorafenib
enhanced the sensitivity of HCC to NK cells via inhibition of6 Clinical and Developmental Immunology
ADAM9 protease activity and modiﬁcation of MICA expres-
sion [33]. However, it has been unclear whether sorafenib
reversestumorescapemechanismsfromhostimmunityafter
recognition of MICA expression. Zhao et al. demonstrated
that sorafenib inhibited the proliferation of T cells and
induced T cell apoptosis and they suggested that sorafenib
may impair T cell-related immunity by inducing apoptosis
[34].Inaddition,Madeleineetal.reportedthatsorafenibsig-
niﬁcantly reduced the induction of antigen-speciﬁc T cells,
impaired the intracellular signaling cascades in DCs, and
induced apoptosis of DCs. They concluded that sorafenib
interferes with the function and maturation of monocyte-
derived DCs [35]. However, it has been unclear whether
sorafenib causes similar changes in LC patients with aHCC.
The present study showed that there were no signiﬁcant
changesofTh1cellsaftertreatmentineachofthe3treatment
groups. In contrast, the percentage of Th2 cells showed a sig-
niﬁcant decrease after treatment in the 400 and 800 groups,
althoughtherewasnosigniﬁcantdiﬀerenceinthe200group.
These results indicate that treatment with sorafenib at doses
of 400mg/day or more can shift host immunity from Th2
dominance to Th1 dominance in LC patients with aHCC,
although sorafenib does not increase number of Th1 cells.
There are two distinct subsets of Treg cells in the periph-
eral lymphoid organs, which are natural Treg (nTreg) cells
that develop in the thymus after recognition of high-aﬃnity
autoantigens, and induced Treg (iTreg) cells that develop
from conventional T cells after peripheral exposure to anti-
gens and cytokines such as TGF-β or IL-10 [36]. These sub-
sets of the Treg network may have a synergistic action or may
have diﬀerent targets that maintain immune homeostasis,
although they possibly even have a developmental role [37].
An increase of circulating and tumor-inﬁltrating FoxP3+
Treg cells has been reported in HCC patients [38]. Sorafenib
is the ﬁrst systemic agent approved for treating HCC and
is a multikinase inhibitor with activity against VEGFR2,
PDGFR, c-Kit receptor, b-RAF, and p38 [39], which are
signal transduction pathways that may be involved in the
pathogenesisofHCC[40].Sorafenibsimultaneously inhibits
several components of the Raf-MEK-ERK signaling pathway,
thus preventing tumor growth and VEGFR-1, VEGFR-2,
VEGFR-3, and PDGFR-b, to inhibit neoangiogenesis [41].
In the present study, the percentage of Treg cells in the
400 group and the 800 group showed a signiﬁcant decrease
after treatment compared with before treatment, although
there was no signiﬁcant diﬀerence after treatment in the 200
group. These results indicate that sorafenib therapy at doses
≥400mg/day inhibited Tregcellsandinduced Th1dominant
host immunity in our LC patients with aHCC. It is possible
that sorafenib achieved this by decreasing iTreg cells through
a reduction of nTreg exposure to HCC antigens by inhibiting
tumor neoagiogenesis.
In the present study, the percentage of Th2 cells showed
a signiﬁcant decrease after treatment in both the PR + SD
group and the PD group, although there was no signiﬁcant
change of Th1 cells after treatment in either group. In
contrast, there were no signiﬁcant diﬀerences of Treg cells
between before and after treatment in either group, although
these cells decreased after treatment in both groups. These
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Figure 9: Possible eﬀect of sorafenib on host immunity. Sorafenib
therapy might abrogate escape mechanisms from the host immu-
nity in LC patients with aHCC by inducing Th1 dominance. DC:
Dendritic cell, Treg: regulatory T cells, Th1: type 1 helper T cells,
Th2: type 2 helper T cells, CTL: cytotoxic CD8+ Tl y m p h o c y t e s .
results indicate that treatment-related changes of host
immunity in LC patients with aHCC might not inﬂuence
the objective response to sorafenib.
In conclusion, we demonstrated that administration
of sorafenib at doses >400mg/day induced Th1 dominant
host immunity in LC patients with aHCC. This eﬀect of
sorafenib therapy might be dependent on two mechanisms,
which are (1) induction of antigen-primed CD4+ Th e l p e r
cells after recognition of MICA expression by HCC cells and
(2) a decrease of Treg cells related to inhibition of tumor
neoangiogenesis. It is also possible that sorafenib might
induce T cell apoptosis or interfere with the function and
maturation of monocyte-derived DCs. Sorafenib therapy
at doses >400mg/day has the potential to abrogate the
mechanisms of tumor escape from the host immune system
in LC patients with aHCC by inducing Th1 dominance
(Figure 9). Accordingly, neoadjuvant therapy with sorafenib
before induction of chemotherapy might prolong the
survival or improve the objective response of LC patients
with aHCC receiving HAIC by modifying host immunity.
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